Roche Expects Sales, Earnings Growth

Roche targets continued growth after strong 2024 sales
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.COWbVb-l.js
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the CEO said it remained committed to keeping its R&D spending broadly flat in 2025.
Roche sees high single-digit core profit growth in 2025
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo.
Roche FY24 Core Operating Profit Rises; Sales Up 7% At CER
Roche (RHHBY) reported that its fiscal 2024 IFRS net income decreased by 19%, or 26% in Swiss francs, to 9.2 billion francs, mainly
Roche Sees Profit Growth Outpacing Sales With Deals Ahead
Roche Holding AG said profit will probably outpace sales growth this year as the Swiss drugmaker works to keep research costs in check and looks for deals to build its pipeline of experimental medicines.
We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings. Boat packed with migrants intercepted amid Trump's mass deportation effort I couldn't get hired for a year—it changed my attitude toward work: 'Perspective comes at an extremely high cost' What we know about the plane and military helicopter crash in D.
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
FiercePharma6h
Eylea-Vabysmo battle wages on as UK marketing watchdog reaffirms Bayer’s claims of ‘misleading’ Roche promos
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
FierceBiotech1d
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
BioSpace1d
Roche to Stay ‘Disciplined’ With Deals in 2025
Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...
FiercePharma1d
Vabysmo crosses $4B mark, Polivy joins blockbuster club as Roche preps for key readouts
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
Wafaa Mamilli To Join Roche As Chief Digital Technology Officer
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.
Roche Bobois Slightly Misses 2024 Revenue Guidance, Says China Boosted Q4
The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...
Roche Holding AG (RHHVF) Gets a Hold from Barclays
Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.
Roche: FDA Approved Label Expansion for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...